Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Comment by Bullknit101on Dec 31, 2020 9:51am
99 Views
Post# 32202671

RE:RE:InMed Moving into 2021

RE:RE:InMed Moving into 2021Stevemin - could you send me the link where it shows the "non office action" for the topical formulation patent formulation? All I saw was "pending" approval from Google advanced patent search. If January doesn't yield any news, than it may be time to scale out and look the Cannabis industry instead, especially if Georgia goes blue. I think the broader market is definately due for a significant correction in January. Mortgage delinquencies, business bankruptcies, Covid out of control in the US, vaccines rollout slow....I'm sure Michael Burry has a few Big Shorts ready to cash in (besides Tesla). The good thing is that InMed likely won't move much on a market downturn, so I will hold for now.
<< Previous
Bullboard Posts
Next >>